Fig. 1From: Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implicationsPVE corrected time-activity curves of 64CuCl2 (as a percentage of injected activity/mL) for the three different site of disease: local (a), lymph node (b) and bone (c) (in red the mean curves)Back to article page